Stejskal, Pavel
Goodarzi, Hani
Srovnal, Josef
Hajdúch, Marián
van ’t Veer, Laura J.
Magbanua, Mark Jesus M.
Funding for this research was provided by:
Ministry of Health of the Czech Republic (NV18-03-00470, NV18-03-00470, NV18-03-00470)
Ministry of Education, Youth and Sport of the Czech Republic (LM2018132, LM2018132, LM2018132)
European Union - Next Generation EU (LX22NPO5102, LX22NPO5102, LX22NPO5102)
European Regional Development Fund (ACGT CZ.02.1.01/0.0/0.0/16_026/0008448, ACGT CZ.02.1.01/0.0/0.0/16_026/0008448, ACGT CZ.02.1.01/0.0/0.0/16_026/0008448)
Era of Hope Scholar (W81XWH-2210121)
The National Institutes of Health (R01CA240984, R01 CA255442, R01 CA255442)
Breast Cancer Research Foundation (BCRF-20-142)
Cancer Cell Mapping Initiative (U54 CA274502)
UCSF Breast Oncology Program Research Development Award, and the Cancer Cell Mapping Initiative (7030559)
Article History
Received: 3 November 2022
Accepted: 29 December 2022
First Online: 21 January 2023
Declarations
:
: Not applicable.
: HG is a stock-holder, board member, and Scientific advisor to ExaiBio Inc. LvtV reports ownership of stocks and part-time employment of Agendia Inc. and is an advisor to ExaiBio Inc. The remaining authors declare no competing interests.